Inotiv/NOTV

$4.71

-2.89%
-
1D1W1MYTD1YMAX

About Inotiv

Inotiv, Inc. is a contract research company, which is engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. The RMS segment offer access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.

Ticker

NOTV

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Robert Leasure

Employees

1,955

Headquarters

West lafayette, United States

Inotiv Metrics

BasicAdvanced
$113.99M
Market cap
-
P/E ratio
-$1.29
EPS
3.37
Beta
-
Dividend rate
$113.99M
3.37007
$11.42
$1.61
449.23K
1.742
1.279
145.943
149.252
0.14%
-3.96%
-12.41%
-4.62%
0.195
0.449
20.316
-0.18%
90.29%
111.54%

What the Analysts think about Inotiv

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 3 analysts.
229.09% upside
High $25.00
Low $10.00
$4.71
Current price
$15.50
Average price target

Inotiv Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-11.29% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$135.5M
-3.7%
Net income
$-15.3M
59.38%
Profit margin
-11.29%
65.54%

Inotiv Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 29.82%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.39
$0.07
-$0.38
-$0.60
-
Expected
-$0.43
-$0.10
-$0.33
-$0.86
-$0.54
Surprise
-8.24%
-170%
15.15%
-29.82%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Inotiv stock?

Inotiv (NOTV) has a market cap of $113.99M as of April 24, 2024.

What is the P/E ratio for Inotiv stock?

The price to earnings (P/E) ratio for Inotiv (NOTV) stock is 0 as of April 24, 2024.

Does Inotiv stock pay dividends?

No, Inotiv (NOTV) stock does not pay dividends to its shareholders as of April 24, 2024.

When is the next Inotiv dividend payment date?

Inotiv (NOTV) stock does not pay dividends to its shareholders.

What is the beta indicator for Inotiv?

Inotiv (NOTV) has a beta rating of 3.37. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Inotiv stock price target?

The target price for Inotiv (NOTV) stock is $15.5, which is 238.43% above the current price of $4.58. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Inotiv stock

Buy or sell Inotiv stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing